Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
95
resultados
Última actualización
27/01/2026 [07:16:00]
Resultados 25 a 50 de 95
Resumen de: CN121022764A
The invention relates to the technical field of biology, in particular to a bacteriophage vBSalPSE29, a bacteriophage vBSalPSE29 preparation and application of the bacteriophage vBSalPSE29 preparation. The invention provides a bacteriophage vBSalPSE29, and the preservation number of the bacteriophage vBSalPSE29 is CGMCC (China General Microbiological Culture Collection Center) No.46499. The bacteriophage vBSalPSE29 is According to the salmonella pullorum bacteriophage provided by the invention, through whole genome sequencing analysis, gene sequences related to lysogenic transformation, antibiotic resistance and virulence factors are not detected in the genome of the salmonella pullorum bacteriophage, so that the biological safety of the bacteriophage for drug development and sterilization product development is ensured from the molecular level, and potential biological risks are effectively avoided.
Resumen de: CN121015906A
The invention relates to the technical field of nano-drug carriers, in particular to a preparation method and application of enzyme-responsive nano-vesicles with pillararene as a carrier, a compound 30 is used as a starting raw material and condensed with a compound 31 under the action of EEDQ to obtain a compound 32, the compound 32 is subjected to Fmoc protection removal through piperidine and diethyl ether precipitation to obtain a compound 33, and the compound 33 is subjected to enzyme-responsive reaction to obtain the enzyme-responsive nano-vesicles with pillararene as the carrier. A compound 33 and a compound 34 react in DMF to obtain a compound 35, the compound 35 is subjected to trifluoroacetic acid deprotection to obtain a compound 36, the compound 36 and a compound 37 react and are subjected to column chromatography separation to obtain a compound 38, the compound 38 and terminal alkyne pillar arene 11 are subjected to 1, 3-dipole addition under the catalysis of Cu I/TBTA to obtain a compound 39, acetyl protecting groups are removed through sodium methoxide to obtain MP5, MP5 is dissolved in deionized water containing 1% of DMSO, dialysis is performed after ultrasonic treatment, and the compound 38 is obtained. The MP5 nano vesicle solves the problem that common antibiotics cannot play a role in intracellular parasitic salmonella, so that infection is difficult to radically treat.
Resumen de: CN121015731A
The invention discloses an extraction method and application of guava functional components for preventing and treating piglet diarrhea. The extraction method comprises the following steps: performing vacuum drying on guava leaves at 45-60 DEG C, and crushing; mixing with an ethanol-water mixed solvent, and carrying out ultrasonic-assisted extraction; filtering the extracting solution, concentrating under reduced pressure, and freeze-drying to obtain the guava leaf extract; according to the scheme, comprehensive prevention and control of bacterial diarrhea are achieved, phenolic compounds in GE directly inhibit growth of ETEC and salmonella, compound enzymes make up the defect that piglet digestive enzymes are insufficient to reduce intestinal burden, and traditional Chinese medicine compounds enhance the intestinal convergence function; the natural plant extract, the traditional Chinese medicine compound and the food-grade enzyme preparation are taken as core components, so that the problems of drug resistance and residue of antibiotics are avoided; ultrasonic-assisted ethanol-water mixed solvent extraction is adopted, and a freeze drying technology is combined, so that the yield of phenolic compounds in GE is increased, the impurity content is reduced, and the raw material cost and the feed palatability influence are reduced.
Resumen de: CN121023055A
The invention discloses an avian salmonella nucleic acid rapid detection method based on a RAA-CRISPR-Cas13a technology and a kit, and belongs to the technical field of biochemistry and molecular biology. On the basis of the designed RAA primer pair and crRNA, the avian salmonella nucleic acid detection based on an RAA-CRISPR-Cas13a enzyme molecular system is established, the system is high in specificity and sensitivity, rapid detection of avian salmonella can be achieved within 30 minutes, the detection sensitivity of a fluorescence method can reach 100 copies/microliter, and the detection sensitivity of a test paper method can reach 102 copies/microliter. In addition, according to the system, expensive test equipment does not need to be operated in a standard professional laboratory, and field detection of clinical samples can be achieved through the portable visual transverse flow test strip.
Resumen de: US2025360189A1
An immunogenic gel compositions for oral administration and methods of immunizing an animal the methods including administering to the animal a therapeutically effective amount of an immunogenic gel composition comprising an antigen of an animal pathogen and a gel composition for oral administration.
Resumen de: WO2025245361A1
The present invention relates to antigen presentation to CD8+ T cells. Systems and methods are provided for efficient presentation of diverse peptide antigens and induction of stimulatory and regulatory CD8+ T cell responses.
Resumen de: CN121003595A
The invention relates to the field of biological pharmacy, in particular to a bacteriophage microcapsule as well as a preparation method and application thereof. The invention provides a bacteriophage microcapsule. The bacteriophage microcapsule comprises 1-5% (w/v) of sodium alginate, 6-10% (w/v) of gelatin, 1.1-3.3% (w/v) of calcium chloride and bacteriophage. According to the invention, salmonella S.Enterica-29 is taken as a host bacterium, microencapsulation coating is carried out on the bacteriophage vB-SalP-SE29, and the bacteriophage has relatively strong lysis activity on the host bacterium. Three materials of sodium alginate, gelatin and CaCl2 are adopted for microencapsulation coating, and on the basis of a single factor test, an optimal preparation condition is obtained through orthogonal test optimization. The microencapsulated bacteriophage vB-SalP-SE29 has the advantages of reducing inflammatory factor expression, relieving inflammatory response and the like, is expected to become an effective antibiotic replacement therapy, and provides a new thought for research of bacteriophage preparations.
Resumen de: CN120989170A
The invention discloses an antibacterial pediococcus pentosaceus cell-free supernatant and an application of the antibacterial pediococcus pentosaceus cell-free supernatant in pork preservation, and belongs to the field of food preservation, the pediococcus pentosaceus is pediococcus pentosaceus YZJC001 and is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC No.33185. The invention further discloses a preparation method of the antibacterial pediococcus pentosaceus cell-free supernatant and an application of the antibacterial pediococcus pentosaceus cell-free supernatant. Compared with other lactic acid bacteria, the cell-free supernatant of the pediococcus pentosaceus has the advantages that the growth of serratia, salmonella typhimurium, staphylococcus aureus and listeria monocytogenes can be obviously inhibited, and the quality guarantee period of the pork can be prolonged after the fresh pork is treated.
Resumen de: CN120988882A
The invention provides copper-loaded duck-origin lactobacillus plantarum with high antibacterial peptide yield and application of the copper-loaded duck-origin lactobacillus plantarum. The preservation number of the provided copper-loaded duck-origin lactobacillus plantarum is CGMCC (China General Microbiological Culture Collection Center) NO.32835. The domesticated and bred duck-origin lactobacillus plantarum with high antibacterial peptide yield can tolerate high-concentration copper ions, the domesticated and bred lactobacillus plantarum can stably grow, and the contents of antibacterial peptide, extracellular protein, lipase, amylase, lactic acid, acetic acid and the like in the domesticated and bred lactobacillus plantarum strain are increased; and the amino acid composition is changed. The strain can convert inorganic copper into organic copper, the utilization rate of copper is increased, and growth and development of organisms are promoted. Moreover, small peptides and extracellular proteins in metabiotics generated after fermentation have the effect of effectively inhibiting harmful bacteria such as riemerella anatipestifer, escherichia coli, salmonella and staphylococcus of poultry, and are beneficial to eliminating intestinal inflammatory factors, maintaining intestinal health and improving the feed utilization rate.
Resumen de: CN120983487A
The invention relates to the technical field of prevention and control of salmonella pullorum, in particular to novel application of lactobacillus rhamnosus P118. The lactobacillus rhamnosus P118 provided by the invention has any one of the following applications: (1) the infection rate of chicks to salmonella pullorum is reduced, (2) the infection rate of the chicks to salmonella pullorum is reduced, (3) the infection rate of the chicks to salmonella pullorum is reduced, and (4) the infection rate of the chicks to salmonella pullorum is reduced; (2) the egg laying performance of hens infected with salmonella pullorum is improved; (3) reducing the bacterial load in the tissues and organs of the hens; (4) reducing horizontal propagation and vertical propagation of salmonella pullorum; and (5) reducing the risk that salmonella pullorum is vertically spread from hens to offspring through eggs. The antagonistic effect of the lactobacillus rhamnosus P118 on pullorum disease in an in-vivo and in-vitro infection model is systematically evaluated, and it is found that the P118 has a remarkable inhibiting effect on colonization infection of the pullorum disease in chick and laying hen models in the egg laying peak period.
Resumen de: CN120989218A
The invention provides a pathogen viable bacteria detection kit based on endogenous protein activated deoxyribozyme. The kit comprises a deoxyribozyme recognition element and a signal transduction element. The deoxyribozyme recognition element is composed of a substrate chain and an enzyme chain, and the signal transduction element is composed of two DNA reporter probes (Sub-F and Sub-Q), wherein the tail ends of the two DNA reporter probes are respectively marked with a fluorescence staining group and a fluorescence quenching group. The deoxyribozyme recognition element can recognize specific endogenous protein of target pathogenic viable bacteria and activate an enzyme chain to cut a substrate chain to generate two independent substrate chain fragments. And then a signal transduction element is introduced to realize specific output of a fluorescence signal. The kit provided by the invention can realize detection of living salmonella by targeting endogenous protein, can sensitively detect 190 CFU/mL of living salmonella with abundance as low as 0.1%, and has a good application prospect in the directions of food safety detection and clinical examination.
Resumen de: CN120989266A
The invention provides a primer group for specifically detecting pathogens in a sample. The primer group comprises at least one of a first primer group for specifically targeting a malB gene of escherichia coli, a second primer group for specifically targeting an invA gene of salmonella and a third primer group for specifically targeting an ipaH gene of shigella. The invention also provides a kit and a detection method for detecting pathogens in a sample by adopting the primer group.
Resumen de: WO2025236040A1
Disclosed herein are solid lipid nanoparticles comprising a fatty acid esterified with polyethylene glycol. The polyethylene glycol is functionalised with an aptamer (i.e. targeting ligand). The nanoparticle may be loaded with an antibiotic or an antifungal, and a fluorescent compound. Also provided are their methods of preparation and their use in drug delivery and biosensing.
Resumen de: WO2025238284A1
The present invention relates to a DNA construct that codes for a fusion protein comprising at least two enterohemorrhagic Escherichia coli antigens, for example, the antigens Int280, EspB, EspA, Stx2B, EspD, combinations or fragments thereof, vectors, fusion protein, immunisation methods and vaccines. The coded antigens can be fused Int280 and EspB of enterohemorrhagic Escherichia coli, forming a fusion protein with or without a connecting sequence between the two. The fused antigens can show the amino acid sequence SEQ ID No. 3 or SEQ ID No. 4 and are coded by the nucleotide sequence in SEQ ID No. 1 and SEQ ID No. 2. The construct can also comprise a signal sequence and a binding sequence for binding to the membrane of bacteria.
Resumen de: CN120202300A
The present invention relates to a DNA construct comprising: a gene encoding flagellin and a gene encoding an immunopotentiator (or adjuvant) protein. In order to achieve effective cancer treatment by selectively killing only cancer cells, the attenuated Salmonella strains of the present disclosure are designed to produce immunogenic substances in cancer tissue to induce a strong anti-cancer immune response to significantly inhibit tumor size in primary and metastatic cancers. Therefore, the strain can be advantageously used in a prophylactic or therapeutic composition for increasing survival rate.
Resumen de: MX2025009500A
The invention relates to the field of vaccine compositions. The invention more particularly relates to a prophylactic vaccine composition that is intended for mammals and birds and comprises a killed whole bacterium, said bacterium being covered with a cationic agent, in particular cationic nanoparticles.
Resumen de: CN120971727A
The invention discloses a method and a kit for simultaneously detecting avian leukosis virus, mycoplasma synoviae and salmonella pullorum antibodies, and belongs to the technical field of animal epidemic disease detection. According to the method, an avian leukosis virus p27 protein, a chicken mycoplasma synoviae p50 protein and a truncated GroEL-delta8-1 protein of a dominant antigen GroEL of salmonella pullorum are taken as coating antigens, synchronous detection of the three antibodies is realized by optimizing ELSA reaction conditions, and a kit capable of simultaneously detecting the three antibodies is developed at the same time. The kit has the characteristics of strong specificity, high sensitivity and simplicity and convenience in operation, is suitable for rapid screening and purification of poultry epidemic diseases, and reduces the detection cost.
Resumen de: CN120960268A
The invention relates to the technical field of nano engineering and probiotics, in particular to a bacteriostatic composition and a fungicide, a veterinary drug and a feed containing the bacteriostatic composition. The invention provides a bacteriostatic composition prepared by simultaneously mixing nano iron sulfide and lactobacillus, which can protect the intestinal colonization ability of lactobacillus and other beneficial bacteria, so that the nano iron sulfide promotes bacterial ferroptosis of pathogenic bacteria in the intestinal tract. The nano iron sulfide and the lactobacillus synergistically inhibit the growth of pathogenic bacteria such as escherichia coli, salmonella typhimurium and staphylococcus aureus in vitro and in intestinal tracts, have no adverse effect on beneficial bacteria and host intestinal epithelial cells, and are beneficial to intestinal health. The invention provides a natural and efficient application mode, and has very high conversion value.
Resumen de: CN120966712A
The invention discloses pediococcus pentosaceus TRM54998 with broad-spectrum antibacterial activity and application of the pediococcus pentosaceus TRM54998, and belongs to the field of microorganisms. The strain is preserved in the China Center for Type Culture Collection (CCTCC) on June 04, 2024, and the preservation number is CCTCC NO: M 20241142. It is proved that the strain has good acid resistance and bile salt resistance and can grow in the environment with the bovine bile salt concentration being 0.1-0.2% (w/v) or in the pH value range being 3-7; the fermentation supernatant has an inhibition effect on nine pathogenic bacteria such as salmonella and the like, and the antibacterial effect is stable; meanwhile, experiments prove that the pediococcus pentosaceus TRM54998 has no wide drug resistance, can relieve the problems of aggravated drug resistance, damage to microbial ecological balance and the like caused by antibiotic abuse, provides a strain resource for preparing a biological bacteriostatic agent or an intestinal probiotic agent, and has a wide application prospect.
Resumen de: CN120966672A
The invention relates to the technical field of microorganisms, in particular to a lactobacillus plantarum strain LM2 and application of the lactobacillus plantarum strain LM2. The strain has relatively high GABA (gamma-aminobutyric acid) production capacity and nitrite degradation capacity, has a bacteriostatic effect on intestinal pathogens such as staphylococcus aureus, salmonella enteritidis, listeria monocytogenes and campylobacter jejuni, has a good bacteriostatic function, also has good acid resistance and cholate resistance, and can be used for preparing a bacterial strain for treating intestinal diseases. The strain can well survive in artificial intestinal juice and artificial gastric juice; in order to increase the yield of GABA, the accelerant capable of remarkably promoting the growth of the strain LM2 is obtained by researching the accelerant, and the highest survival rate of the freeze-dried powder prepared by optimizing the accelerant and the freeze-dried powder can reach 99% or above, the nitrite degradation rate can reach 99% or above, the yield of GABA is increased to 3.0 g/L or above, and the freeze-dried powder is bacterial powder capable of being widely applied.
Resumen de: CN120960461A
The invention discloses a lactoferrin modified florfenicol nano-liposome (R-FL) as well as a preparation method and application thereof. The R-FL is prepared by adopting a technology of combining an improved reversed-phase solvent evaporation method and chemical coupling. The R-FL disclosed by the invention is strong in slow and controlled release capability and good in biocompatibility, has excellent in-vitro and in-vivo antibacterial effects, and can be used for inhibiting the formation of a biofilm by precisely damaging the structure of the biofilm of the drug-resistant salmonella typhimurium in a targeting manner. The R-FL can effectively regulate the intestinal flora disorder caused by the drug-resistant salmonella typhimurium, so that the intestinal flora is recovered to a normal level. The R-FL can be used as a novel nano preparation with great potential for resisting drug-resistant salmonella typhimurium disease, and has a wide application prospect.
Resumen de: CN120966710A
The invention discloses a strain of lactobacillus parabarium LN43 and application thereof, and belongs to the technical field of microorganisms. The preservation number of the lactobacillus parabarium LN43 is GDMCC No.66615, the preservation unit is Guangdong Province Microbial Culture Collection Center, the preservation time is June 30, 2025, and the address of the preservation unit is the 5th floor, No. 59 building, No. 100 Courtyard, Xianlie Middle Road, Guangzhou City. The lactobacillus parabarium LN43 has the advantages that the lactobacillus parabarium LN43 has the preservation number of GDMCC No.66615, the preservation number is GDMCC No.66615, the preservation unit is Guangdong Province, the preservation time is June 30, 2025, and the preservation unit is the June 30, 2025. The lactobacillus parabarium LN43 has relatively high acid resistance and a certain cholate tolerance. The lactobacillus parabarium LN43 has the advantages of high acid resistance and certain cholate tolerance. The strain has a very strong inhibition effect on pathogenic microorganisms such as staphylococcus aureus, salmonella pullorum, salmonella enteritidis, escherichia coli, pseudomonas aeruginosa, salmonella typhimurium, micrococcus luteus, acinetobacter baumannii and klebsiella pneumoniae, and is a broad-spectrum antibacterial microorganism.
Resumen de: CN120967021A
The invention provides a product for detecting eight food-borne pathogenic bacteria by time-of-flight mass spectrometry, which comprises a specific primer group of multiple PCR (Polymerase Chain Reaction) of the eight food-borne pathogenic bacteria, wherein the food-borne pathogenic bacteria comprise intestinal aggregation Escherichia coli, intestinal hemorrhagic Escherichia coli, intestinal invasive Escherichia coli, intestinal pathogenic Escherichia coli, Shiga toxin producing Escherichia coli, enterotoxin producing Escherichia coli, listeria monocytogenes and salmonella typhimurium. The detection vehicle product is used for carrying out multiple PCR amplification on pathogen DNA, and the size of a fragment of the multiple PCR product is detected through MALDI-TOF MS (matrix-assisted laser desorption/ionization time of flight mass spectrometry). According to the method, multiple PCR and MALDI-TOF MS are combined to be used for identifying clinical pathogenic microorganisms, and the method is rapid, simple, convenient, easy to observe, visual and high in accuracy.
Resumen de: CN117838855A
The invention relates to a synthetic adhesive for limiting passage through mucus. Synthetic adhesives for reducing the proportion of targets that can traverse mucus and/or free cleavage are disclosed, as well as methods of using these synthetic adhesives to reduce mucosal penetration and/or free cleavage of targets.
Nº publicación: CN120960359A 18/11/2025
Solicitante:
TIBET VOCATIONAL TECHNICAL COLLEGE
\u897F\u85CF\u804C\u4E1A\u6280\u672F\u5B66\u9662
Resumen de: CN120960359A
The invention relates to the technical field of animal medicines, and particularly discloses a veterinary medicine compound preparation as well as a preparation method and application thereof. The veterinary medicine compound preparation is prepared by boiling, extracting, concentrating and diluting eight Tibetan medicines including aconitum pendulum, fructus chebulae, radix inulae inula, benzoin, pterocephalus hookeri, lagotis lagotis, amomum tsao-ko and rhodiola rosea. The veterinary drug compound preparation provided by the invention has an antibacterial range of 8.67 mm to 23.77 mm on enterotoxic large intestine dried bacteria, salmonella enteritidis and pasteurella multocida, and has an inhibition rate of 60% to 72% on enterotoxigenic escherichia coli diarrhea, salmonella enteritidis diarrhea and pasteurella multocida diarrhea; therefore, the veterinary drug compound preparation provided by the invention has a remarkable inhibition effect on enterotoxic large intestine dry bacteria, salmonella enteritidis and pasteurella multocida.
BOPI
Sede Electrónica
